A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential ...
Discovery reshapes understanding of how tumor cells repair broken DNA, pointing toward more precise cancer therapies.
DNA repair proteins act like the body's editors, constantly finding and reversing damage to our genetic code. Researchers have long struggled to understand how cancer cells hijack one of these ...
Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations. This is an ASCO ...
The MarketWatch News Department was not involved in the creation of this content. CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 -- Artios Pharma Limited ("Artios"), a biopharmaceutical ...
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals ...
The MCM helicase is broadly bound across the genome, and its phosphorylation is antagonistically regulated by the kinase DDK and the phosphatase RIF1–PP1. TRESLIN–MTBP recognises the phosphorylated ...
Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer. Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss ...
– Independent prospective analysis validates theta-band inter-trial coherence (ITC) as an important, objective measure to distinguish patients with schizophrenia from healthy individuals – – A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results